. Remdesivir of scant benefit in hospitalized COVID patients, study finds - IOPAC Press "Enter" to skip to content

International Pathogen Surveillance Network announces first recipients of grants to better understand disease threats
- All WHO news
The World Health Organization (WHO) and partners announced 10 projects that will receive almost US$ 2 million in grants to...
The first-ever global oral health conference highlights universal health coverage by 2030
- All WHO news
Delegations from over 110 countries are coming together to produce national roadmaps and negotiate a joint declaration on oral health...
Lebanon: a conflict particularly destructive to health care
- All WHO news
Since 7 October 2023, 47% of attacks on health care – 65 out of 137 – have proven fatal to...

The right to health
- WHO Director-General speeches
Excellencies, ladies and gentlemen, Good afternoon, and thank you for having me. It’s a real honour to be with you...
Closing address at High-Level Action Day, First WHO Global Conference on Air Pollution and Health
- WHO Director-General speeches
Every human being is entitled to breathe clean air. It’s a human right. We are honoured to have the Human...
Opening address at the First WHO Global Conference on Air Pollution and Health
- WHO Director-General speeches
Excellency, second Lady Hajia Samira Bawumia of Ghana, my colleague colleague Dr Taalas, Secretary General of WMO and my sister...

Remdesivir of scant benefit in hospitalized COVID patients, study finds

By iopac on August 24, 2020

Mary Van Beusekom | News Writer | CIDRAP NewsAug 24, 2020The data add to a mixed picture of the drug in randomized clinical trials.

Published in COVID-19

iopac